Predict your next investment

Corporation
guanhaobio.com

See what CB Insights has to offer

Investments

1

About Guanhao Biotech

Guanhao Biotech (冠昊生物) (300238.SZ) focuses on regenerative medicine industry, which includes continuous biomaterials, cells/stem cells, pharmaceuticals, advanced medical technologies, and products.

Guanhao Biotech Headquarter Location

12 Yuyan Rd Huangpu District

Guangzhou, Guangdong,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Guanhao Biotech News

Nearly 20 Chinese Firms Try to Make World's No. 1 New Coronavirus Vaccine

Feb 10, 2020

1 New Coronavirus Vaccine (Yicai Global) Feb. 10 -- Almost 20 Chinese companies, including Kangtai Biological Products and Guanhao Biotech, are striving to create the world's first vaccine against the new coronavirus. Researchers in these 17 firms have been working around the clock, trying to develop inactivated, DNA, subunit, and viral vector vaccines as of Feb. 6, the China Association for Vaccines said in a report posted on WeChat yesterday. The novel coronavirus epidemic that started spreading from Central China's Hubei province has claimed 909 lives and infected over 40,200 people in the country. Kangtai's stock price [SHE: 300601] climbed nearly 8 percent this morning to CNY109.84 (USD15.71) after the Shenzhen-based company said yesterday that it has joined hands with Beijing's Advaccine Biotechnology to speed up the vaccine development process. But success would not yet show in this year's business performance, it added. Guanhao announced on Feb. 3 that it is teaming up with North Carolina's ZY Therapeutics to make a DNA vaccine for the same purpose. Its shares [SHE: 300238] walked back some of their gains accumulated over last week today. Zhifei Biological Products said on Feb. 2 that the Chongqing-based firm has similar business ambitions, supported by an institute under the Chinese Academy of Sciences. Its stock price [SHE: 300122] rose 2.6 percent to CNY64.40 (USD9.21) this morning. Editor: Emmi Laine

Guanhao Biotech Investments

1 Investments

Guanhao Biotech has made 1 investments. Their latest investment was in Zy Therapeutics as part of their Secondary Market on September 9, 2019.

CBI Logo

Guanhao Biotech Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/19/2019

Secondary Market

Zy Therapeutics

$3.1M

Yes

4

Date

9/19/2019

Round

Secondary Market

Company

Zy Therapeutics

Amount

$3.1M

New?

Yes

Co-Investors

Sources

4

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.